Can Calidi Biotherapeutics, Inc.’s RedTail platform solve the solid tumor T-cell engager problem?
Calidi Biotherapeutics, Inc. unveils new RedTail and TROP-2 data at AACR 2026. Read what this means for solid tumor immunotherapy and CLD-401 next.
How electroCore, Inc. is strengthening the clinical case for bioelectronic medicine in trauma-related brain injury
electroCore, Inc.’s latest data could reshape bioelectronic medicine in trauma-related brain injury. Read what clinicians and industry watchers may track next.
What Ocugen, Inc.’s OCU410ST milestone means for the race to treat inherited retinal blindness
Discover what Ocugen, Inc.’s OCU410ST milestone means for the future of inherited retinal blindness treatment and the race toward first approval.
How Cogent Biosciences, Inc.’s bezuclastinib filing could redefine the second-line treatment paradigm in gastrointestinal stromal tumors
Cogent Biosciences files bezuclastinib NDA in second-line GIST. Explore what the PEAK data could change for clinicians, regulators, and investors.
Can Merck’s enlicitide decanoate become the oral PCSK9 breakthrough cholesterol care has been waiting for?
Merck’s enlicitide decanoate beat oral rivals in Phase 3. Read what this could change for cholesterol care, PCSK9 adoption, and market strategy.
Can Merck expand WINREVAIR beyond pulmonary arterial hypertension after CADENCE data?
Can Merck turn WINREVAIR’s CADENCE data into a new treatment path in CpcPH-HFpEF? Read the full analysis of what changes next.
Why WINREVAIR’s Phase 2 data matters beyond pulmonary arterial hypertension
CADENCE trial data shows sotatercept’s promise in HFpEF-linked pulmonary hypertension. Find out what this means for treatment and regulation.
What the NEOK002 IND milestone changes for Biocytogen, NEOK Bio, and ADC competition
NEOK002 has cleared the FDA IND stage. Read why this bispecific ADC matters for solid tumors, clinical strategy, and the next phase of ADC competition.
Can Merck’s $6.7bn Terns takeover turn TERN-701 into a post-Keytruda oncology pillar?
Merck is buying Terns for TERN-701. Read why this CML deal could reshape its hematology strategy and what risks still remain.
Academic partnerships signal Propanc Biopharma, Inc. push into aging biology and tumor resistance science
Propanc Biopharma expands Spanish research alliances ahead of first human oncology trials. Discover what this means for PRP development and strategy.